Efficacy Of Gastrointestinal Pacemaker In Treatment With Disorders Of Gastromotility

Background and Purpose: Mechanism and regulation of gastrointestinal motility have been much futher investigated in recent ten years. Clinically, disorders of gastrointestinal motility are a very common disease. With the development of the understanding of the gastrointestinal tract structure, the clearer understanding of the gastrointestinal ICC position, and the rapid growth of the electronic technology, gastrointestinal pacemaking as a new method to treat disorders of gastrointestinal motility has attracted wide attention. The basic principle of gastrointestinal pacemaking: the electro-activity of human being抯 gastrointestinal pacemaker can be driven by external electric current. Electronic technology can generate a similar bio-electrical signal as that of a human being抯 basic electrical pace. By choosing the right requency 4 ~ifE~ 2001 ~ and amplitude, the bio-electrical signal can be impose on a human being抯 gastrointestinal pacemaker through the body skin. This will cause the human being抯 gastrointestinal pacemaker to have a follow-up effect, and force the human being抯 gastrointestinal pacemaker to have the normal frequency and amplitude. This way it will reduce or eliminate the symptoms of the stomach functional disease. And therefore, disorders of gastrointestinal motility could be cured. We investigated the efficacy and safety of treatment with gastrointestinal pacemaker. Patients and Methods: Randomized studies were performed in a total of sixty patients with postprandial fullness, epigastric pain, epigastric fullness, belch, nausea, hypercoria, anorexia, vomiting, or more than tow of these symptoms and at least for four weeks. Thirty patients were treated with gastrointestinal pacemaker for ten days, thirty minutes daily (treatment group); fifteen patients were treated with gastrointestinal empty pacemaker for ten days as control (control group), thirtyminutes daily; fifteen patients received treatment with cisapride (cisapride group) for ten days, 5mg three times daily, thirty minutes before meal. Electrogastrograms were performed on pre and post treatments, wrote down the mean freqLlency and mean amplitude, wrote down the clinical symptoms and untoward reactions. Results: Total efficacy of treatment group, control group and cisapride group were 96.2%, 58.0%, and 91.7% respectively. The total points of the symptoms 5 2001 ~ were significantly decreased after treatment with gastrointestinal pacemaker and ciaspride (p